Indian Journal of Dermatology最新文献

{"title":"Clinical Profile of Neurofibromatosis Type 1: Paediatric Patients from a Tertiary Care Centre.","authors":"Vibhu Mendiratta, Bharati Verma, Ayushman Bindal","doi":"10.4103/ijd.ijd_389_25","DOIUrl":"10.4103/ijd.ijd_389_25","url":null,"abstract":"<p><p>Neurofibromatosis Type 1 (NF1) is a genetic disorder involving multiple organ systems, primarily the nervous system and skin. It presents with diverse cutaneous, neurological, and systemic manifestations, many of which appear early in life (under 5 years of age). Early recognition of its clinical features is crucial for timely, multidisciplinary management. There is limited data on the clinical profile of paediatric NF1 in India. This case series describes the clinical characteristics of children diagnosed with NF1 in a tertiary care centre. The aim was to describe the clinical and systemic features of paediatric NF1 in the Indian population. Objectives included identifying early cutaneous signs, evaluating systemic involvement, assessing family history patterns, and emphasising the need for early diagnosis and coordinated care. The study was conducted at the paediatric dermatology outpatient department of a tertiary care hospital in Delhi. Records from a dedicated genodermatosis clinic were reviewed. Children fulfilling the NIH diagnostic criteria for NF1 were included. Clinical features, imaging findings, and systemic associations were extracted and analysed. Among 25 children diagnosed with NF1, 15 were females and 10 were males, with age at diagnosis ranging from 2 to 18 years. A positive family history was noted in 52% of cases. Café-au-lait macules (CALMs) were seen in all patients; 80% had them at birth. Neurofibromas were observed in 64%, including plexiform neurofibromas in 8%. Intertriginous freckling and Lisch nodules were each noted in 52% of cases. Developmental delay was seen in 24%, with gross motor and speech delays. Scoliosis was identified in 12%. No oral or cardiovascular abnormalities were found. This study highlights the importance of early dermatological and systemic screening in children with NF1. Timely recognition of clinical signs is essential for effective multidisciplinary management.</p>","PeriodicalId":13401,"journal":{"name":"Indian Journal of Dermatology","volume":"71 4","pages":"306-309"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13336537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148436548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Heartfulness Meditation as Adjunctive Therapy for Moderate to Severe Psoriasis: A Randomised Controlled Trial.","authors":"Prabhakaran Nagendran, Senthil K Subramanian, Satyanarayanan, Vidya D Sripad, Rajathi Rajendran, Hima Gopinath, Kode L Sravanthi, Haritha Thiruveedhula","doi":"10.4103/ijd.ijd_858_24","DOIUrl":"10.4103/ijd.ijd_858_24","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic inflammatory skin condition significantly impacting quality of life. Traditional treatments, such as methotrexate, are effective but often have side effects and do not address psychosocial stressors. Heartfulness meditation, which emphasises relaxation and self-awareness, may complement standard treatments by reducing stress.</p><p><strong>Objective: </strong>The primary objective was to evaluate the effectiveness of heartfulness meditation as an adjunct to methotrexate in achieving a 75% reduction in Psoriasis Area and Severity Index (PASI 75) at 4 months. Secondary objectives included changes in body surface area (BSA), Dermatology Life Quality Index (DLQI), Perceived Stress Scale (PSS), Pittsburgh Sleep Quality Index (PSQI), and biomarkers (serum cortisol and IL-6 levels).</p><p><strong>Methods: </strong>This randomised controlled trial was conducted at the dermatology outpatient department of the institute, India, involving 50 adults (18-60 years) with moderate to severe psoriasis (PASI ≥10 or BSA involvement ≥10%). Participants were randomised into two groups: the intervention group (n = 25) received heartfulness meditation alongside methotrexate (7.5 mg to 25 mg weekly), while the control group (n = 25) received methotrexate alone. Randomisation used a computer-generated sequence, with blinding applied to outcome assessors and data analysts.</p><p><strong>Results: </strong>Of the 50 participants randomised, 44 were included in the final analysis. PASI 75 was achieved in 61.1% of the intervention group compared to 52.38% in the control group (<i>P</i> = 0.548). Trends towards better improvements in BSA, DLQI, PSS, and PSQI were observed in the intervention group, though not statistically significant. Both groups showed reductions in serum cortisol and IL-6 levels, with slightly greater reductions in the intervention group. No adverse events related to heartfulness meditation were reported.</p><p><strong>Conclusion: </strong>Heartfulness meditation may offer additional benefits when combined with methotrexate for treating moderate to severe psoriasis, though findings were not statistically significant. Larger studies are needed to confirm these results.</p>","PeriodicalId":13401,"journal":{"name":"Indian Journal of Dermatology","volume":"71 4","pages":"333"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13336643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Results of Nail Correction with Distal Phalanx Osteotomy for Pincer Nail Deformity: A Retrospective Cohort Study.","authors":"Kang Wu, Hongrui Wang, Weiye Zhang, Tianyu Gao, Xiaoxu Wang, Ning Zhang, Juan Wang","doi":"10.4103/ijd.ijd_371_25","DOIUrl":"10.4103/ijd.ijd_371_25","url":null,"abstract":"<p><strong>Background: </strong>Pincer nail deformity (PND) is characterized by excessive transverse curvature of the nail plate, often causing pain, functional impairment, and poor cosmesis. Existing treatments focusing on the soft tissue correction frequently result in recurrence.</p><p><strong>Aims and objectives: </strong>To evaluate the long-term efficacy and safety of a novel distal phalanx osteotomy technique in correcting the anatomical basis of PND and alleviating associated symptoms.</p><p><strong>Materials and methods: </strong>A retrospective cohort study was conducted on 51 cases (39 patients) with PND, who underwent inverted V-shaped distal phalanx osteotomy between May 2013 and January 2022. Nail morphology indices, pain levels, and satisfaction scores were assessed pre- and post-operatively. Statistical analysis was performed using paired <i>t</i>-tests. Institutional review board (IRB) approval was obtained.</p><p><strong>Results: </strong>Postoperative assessments showed significant morphological improvement: the width index increased from 69.1% to 95.9% and the height index decreased from 64.5% to 13.8% (<i>P</i> < 0.001 for both). Pain visual analogue scale (VAS) decreased from 7.5 to 1.8, while satisfaction VAS improved from 1.4 to 9.0 (<i>P</i> < 0.001). No recurrences, nail growth arrest, or complications were observed during a mean follow-up of 3.3 years.</p><p><strong>Conclusion: </strong>Distal phalanx osteotomy offers a durable, anatomically corrective approach to treating PND. By remodelling both the osseous and soft tissue structures, it effectively prevents recurrence and restores functional nail architecture.</p>","PeriodicalId":13401,"journal":{"name":"Indian Journal of Dermatology","volume":"71 4","pages":"280-283"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13336646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148436519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Therapeutic Challenge in a Rare Case of Immunoglobulin A Type of Epidermolysis Bullosa Acquisita.","authors":"Shreya K Gowda, Biswanath Behera, Madhusmita Sethy, Pavitra Ayyanar","doi":"10.4103/ijd.ijd_179_25","DOIUrl":"10.4103/ijd.ijd_179_25","url":null,"abstract":"","PeriodicalId":13401,"journal":{"name":"Indian Journal of Dermatology","volume":"71 3","pages":"231-233"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13155713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147868163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facial Melanosis: A Comprehensive Review of Uncommon and Common Presentations with Personal Experience.","authors":"Rashmi Sarkar, Damini Verma","doi":"10.4103/ijd.ijd_159_25","DOIUrl":"10.4103/ijd.ijd_159_25","url":null,"abstract":"<p><p>Facial melanoses (FMs) encompass a diverse group of disorders characterised by altered facial pigmentation, particularly prevalent in individuals with darker skin types, such as the Indian population. While common causes like melasma, post-inflammatory hyperpigmentation, and lichen planus pigmentosus are well documented in the literature, this review emphasises the lesser-known and uncommon causes of FM. These include facial acanthosis nigricans, maturational hyperpigmentation, frictional facial melanosis, and seborrheic melanosis, which are frequently observed in Indian populations but remain underrecognised and understudied. The aetiology of FM is multifactorial, involving genetic predisposition, racial factors, ultraviolet radiation, and exposure to photosensitising chemicals and allergens. Uncommon causes often present unique diagnostic challenges and are frequently misdiagnosed due to their overlapping clinical features. Diagnosis relies on clinical evaluation, supported by Wood's lamp examination, dermoscopy, and, in some cases, skin biopsy. FM can be classified into brown, blue, or mixed hypermelanosis based on the location and nature of melanin deposition. Management of these uncommon conditions is complex and requires a nuanced approach. Photoprotection remains a cornerstone of therapy, alongside topical depigmenting agents, chemical peels, and laser or light-based interventions. However, the risk of post-inflammatory hyperpigmentation in richly pigmented skin necessitates cautious and individualised treatment strategies. The lack of standardised guidelines for these uncommon causes further complicates management, underscoring the need for tailored therapeutic approaches. This review highlights the clinical significance of recognising and addressing uncommon causes of FM, which significantly impact patients' quality of life and psychosocial well-being. Enhanced awareness, further research, and the development of evidence-based treatment protocols are essential to improve outcomes for patients with these understudied conditions. By focussing on these uncommon causes, this review aims to fill a critical gap in the literature and provide a comprehensive resource for clinicians managing facial melanoses in skin of colour. Such comprehensive articles are lacking in literature.</p>","PeriodicalId":13401,"journal":{"name":"Indian Journal of Dermatology","volume":"71 3","pages":"171-184"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13155718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147868205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Syringofibroadenoma of Atypical Presentation: Dermoscopic Features in a Poorly Described Entity.","authors":"Martín N Céspede, Pablo A Vargas, Claudia M Morales","doi":"10.4103/ijd.ijd_5_24","DOIUrl":"10.4103/ijd.ijd_5_24","url":null,"abstract":"<p><p>Syringofibroadenoma is a benign proliferation of the eccrine ducts which is thought to originate as a reactive hyperplasia to other skin conditions. It usually presents as a solitary, hyperkeratotic or verrucous plaque or nodule on the extremities in elderly patients. We report the case of a 32-year-old male who presents with a pink papule on the left chest for several years. The histopathological manifestation was consistent with the diagnosis of syringofibroadenoma. We focus on the atypical clinical presentation and dermoscopic findings, given that despite there being multiple cases reported in the international literature, its dermoscopic characteristics have not been described.</p>","PeriodicalId":13401,"journal":{"name":"Indian Journal of Dermatology","volume":"71 3","pages":"243-245"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13155704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147868150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Abrocitinib in Cyclosporine-Resistant Atopic Dermatitis: A Real-world Experience from the Indian Subcontinent.","authors":"Abhishek De, Disha Chakraborty, S K Shahriar Ahmed, Smriti Gupta, Sandipan Dhar, Manas Chatterjee","doi":"10.4103/ijd.ijd_516_25","DOIUrl":"10.4103/ijd.ijd_516_25","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and eczematous lesions. Abrocitinib, a selective Janus kinase 1 (JAK1) inhibitor, has recently been approved in India for moderate-to-severe AD in adults. This prospective real-world case series evaluated the effectiveness and safety of abrocitinib in patients with moderate-to-severe AD who showed an inadequate response to cyclosporine. Nine patients (five females, four males; mean age 19.44 ± 7.68 years, range 10-34 years) were included. Three were adolescents or children in whom abrocitinib was used off-label. The mean disease duration was 13.33 ± 8.06 years, and eight patients had a positive family history of AD. Prior treatments included cyclosporine, methotrexate, and systemic corticosteroids. Abrocitinib was prescribed at a mean dose of 177.77 ± 44.09 mg daily (seven patients received 200 mg, two received 100 mg). Effectiveness was assessed at baseline and weeks 2, 4, 8, and 12 using the Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), and Peak Pruritus Numerical Rating Scale (PP-NRS). Significant and progressive reductions were observed in all scores. Mean EASI decreased from 48.22 ± 7.88 at baseline to 6.33 ± 3.35 at week 12 (<i>P</i> < 0.0001). IGA scores improved from 4 to 1.22 ± 0.44, while PP-NRS declined from 8.44 ± 0.52 to 2 ± 0.86 by week 12, with significance evident early in treatment. Most patients demonstrated good adherence, and dose adjustments were required in some cases. One patient developed mild thrombocytopenia. Abrocitinib demonstrated rapid, significant clinical improvement and was generally well-tolerated, supporting its role as an effective option for moderate-to-severe AD, particularly in patients with inadequate response to cyclosporine.</p>","PeriodicalId":13401,"journal":{"name":"Indian Journal of Dermatology","volume":"71 3","pages":"234-238"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13155721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147868160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pseudohypoparathyroidism with Turner's Syndrome.","authors":"Mohd Shurjeel Ul Islam, Najam U Saqib, Mir Umar Farooq","doi":"10.4103/ijd.ijd_832_24","DOIUrl":"10.4103/ijd.ijd_832_24","url":null,"abstract":"","PeriodicalId":13401,"journal":{"name":"Indian Journal of Dermatology","volume":"71 3","pages":"247-249"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13155706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147868168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erythema Multiforme Presenting as Polymorphic Morphology Along with Acute Generalized Exanthematous Eruption-like Lesions: A Rare Presentation.","authors":"Vidya Yadav, Vibhu Mendiratta, Md Ali Osama","doi":"10.4103/ijd.ijd_1170_23","DOIUrl":"10.4103/ijd.ijd_1170_23","url":null,"abstract":"","PeriodicalId":13401,"journal":{"name":"Indian Journal of Dermatology","volume":"71 3","pages":"250-253"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13155707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147868200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Quality of Life and Family Impact in Adult Atopic Dermatitis Patients Compared to Chronic Spontaneous Urticaria and Psoriasis: A Comparative Cross-Sectional Study.","authors":"Gonca Saraç, Andaç Salman, Sinem Örnek, Elif Gökçe, Kübra Esen Salman, Emek Kocatürk Göncü","doi":"10.4103/ijd.ijd_185_24","DOIUrl":"10.4103/ijd.ijd_185_24","url":null,"abstract":"","PeriodicalId":13401,"journal":{"name":"Indian Journal of Dermatology","volume":"71 3","pages":"249-250"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13155715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147868195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}